Abstract
Many proteins are transported from the nucleus to the cytoplasm by the exportin CRM1, which recognizes cargo proteins through a leucine rich nuclear export signal (NES). This nuclear export process can be inhibited by several small molecules, both natural products and fully synthetic compounds. The structural basis for the inhibition of nuclear export by leptomycin (LMB) based on disruption of the protein/protein interaction between CRM1 and cargo proteins is discussed. The chemistry and inhibition of nucleocytoplasmic transport of leptomycin, anguinomycin and derivatives, goniothalamin, JBIR-02, valtrate, dihydrovaltrate, ACA, peumusolide A and several synthetic compounds are presented. Consequences for the design of nuclear export inhibitors are discussed, and the potential of these compounds as anticancer agents is evaluated.
Keywords: Nuclear export, natural products, chemical biology, anticancer compounds, cell biology, biopolymers, chemical genetics, protein/protein interaction, chemical inteference, phenotypes
Current Drug Targets
Title: Controlling Protein Transport by Small Molecules
Volume: 12 Issue: 11
Author(s): Karl Gademann
Affiliation:
Keywords: Nuclear export, natural products, chemical biology, anticancer compounds, cell biology, biopolymers, chemical genetics, protein/protein interaction, chemical inteference, phenotypes
Abstract: Many proteins are transported from the nucleus to the cytoplasm by the exportin CRM1, which recognizes cargo proteins through a leucine rich nuclear export signal (NES). This nuclear export process can be inhibited by several small molecules, both natural products and fully synthetic compounds. The structural basis for the inhibition of nuclear export by leptomycin (LMB) based on disruption of the protein/protein interaction between CRM1 and cargo proteins is discussed. The chemistry and inhibition of nucleocytoplasmic transport of leptomycin, anguinomycin and derivatives, goniothalamin, JBIR-02, valtrate, dihydrovaltrate, ACA, peumusolide A and several synthetic compounds are presented. Consequences for the design of nuclear export inhibitors are discussed, and the potential of these compounds as anticancer agents is evaluated.
Export Options
About this article
Cite this article as:
Gademann Karl, Controlling Protein Transport by Small Molecules, Current Drug Targets 2011; 12 (11) . https://dx.doi.org/10.2174/138945011798109446
DOI https://dx.doi.org/10.2174/138945011798109446 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Will Pharmacogenetics Predict Response to Therapies in Rheumatoid Arthritis?
Current Pharmacogenomics Computational Medicinal Chemistry to Design Novel Phosphoinositide 3- Kinase (PI3K) Alpha Inhibitors in View of Cancer
Current Bioactive Compounds Towards Breast Cancer Vaccines, Progress and Challenges
Current Drug Discovery Technologies Synthesis and In Vitro Anticancer Activity of 6-Ferrocenylpyrimidin-4(3H)-one Derivatives
Current Organic Synthesis Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) The Role of microRNAs in the Diagnosis and Treatment of Malignant Pleural Mesothelioma - A Short Review
MicroRNA Adverse Reactions to Fluoroquinolones. An Overview on Mechanistic Aspects
Current Medicinal Chemistry Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design Chitosan and its Derivatives as Chemical Drug Delivery Carriers
Current Organic Chemistry Bilosomes: A Novel Approach to Meet the Challenges in Oral Immunization
Recent Patents on Drug Delivery & Formulation Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB family of Receptor Tyrosine Kinases: First Step in the Development of Therapeutic Antibody/Liposomal Anticancer Drug Combinations
Letters in Drug Design & Discovery Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology The Role on Endoscopy in Alcohol-Related Diseases
Reviews on Recent Clinical Trials Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Mechanisms of Viral Hepatitis Induced Liver Injury
Current Molecular Medicine Modulation of MMPs by Cell Surface Integrin Receptor α5β1
Anti-Cancer Agents in Medicinal Chemistry Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
Recent Patents on Anti-Cancer Drug Discovery